Fructose-1,6-bisphosphatase (FBP)-1 is a gluconeogenic enzyme that regulates glucose metabolism and insulin secretion in ␤ cells, but little is known about how its transcription is controlled. The zinc finger protein ZBTB20 regulates glucose homeostasis, so we investigated its effects on expression of FBP-1. METH-ODS: We analyzed gene expression using real-time reverse-transcription polymerase chain reaction, immunoblotting, and immunohistochemistry. We generated mice with ␤ cell-specific disruption of Zbtb20 using Cre/LoxP technology. Expression of Zbtb20 in ␤ cells was reduced using small interfering RNAs, and promoter occupancy and transcriptional regulation were analyzed by chromatin immunoprecipitation and reporter assays. RESULTS: ZBTB20 was expressed at high levels by ␤ cells and other endocrine cells in islets of normal mice; expression levels were reduced in islets from diabetic db/db mice. Mice with ␤ cell-specific knockout of Zbtb20 had normal development of ␤ cells but had hyperglycemia, hypoinsulinemia, glucose intolerance, and impaired glucose-stimulated insulin secretion. Islets isolated from these mice had impaired glucose metabolism, adenosine triphosphate production, and insulin secretion after glucose stimulation in vitro, although insulin secretion returned to normal levels in the presence of KCl. ZBTB20 knockdown with small interfering RNAs impaired glucose-stimulated insulin secretion in the ␤ cell line MIN6. Expression of Fbp1 was up-regulated in ␤ cells with ZBTB20 knockout or knockdown; impairments to glucose-stimulated insulin secretion were restored by inhibition of FBPase activity. ZBTB20 was recruited to the Fbp1 promoter and repressed its transcription in ␤ cells. CONCLUSIONS: The transcription factor ZBTB20 regulates ␤ cell function and glucose homeostasis in mice. It might be a therapeutic target for type 2 diabetes mellitus.
P
ancreatic ␤ cells play a critical role in glucose homeostasis by secreting insulin in a tightly controlled manner, the progressive dysfunction of which is one of the pathological characteristics of type 2 diabetes mellitus (T2DM). 1 Through a metabolism-secretion coupling system, ␤ cells can precisely sense glucose stimulation by its conversion into metabolic intermediates including adenosine triphosphate (ATP) and accordingly adjust insulin secretion by closure of ATP-sensitive K ϩ channels and influx of Ca 2ϩ . 2, 3 In past decades, some critical components of glucose-sensing machinery in ␤ cells have been established, which include the facilitative glucose transporter GLUT2, glucokinase (Gk), and the glycolytic enzyme phosphofructokinase (PFK). 1, 4, 5 Recent reports indicate that fructose-1,6-bisphosphatase (FBPase), a ratelimiting gluconeogenic enzyme, plays a role in regulating glucose sensing and insulin secretion of ␤ cells. 6 -8 FBPase controls the futile recycling between fructose-6-phosphate and fructose-1,6-bisphosphate by coupling with PFK, thus regulating the glycolytic/gluconeogenic flux. 9 FBPase has FBP1 and FBP2, 2 distinct isoenzymes in mammals that are preferentially expressed in liver and muscle, respectively. 10 FBP1 is also expressed in human and rodent islets 6 and acts as a regulator of glucose metabolism and insulin secretion in ␤ cells. 8 More importantly, it is implicated in ␤ cell dysfunction in the pathogenesis of T2DM. Fbp1 expression is up-regulated both in the islets from patients with T2DM and in the ␤ cells after exposure to hyperglycemia or treatment with lipid. 7, [11] [12] [13] Transgenic overexpression of Fbp1 in ␤ cells leads to impaired glucose-stimulated insulin secretion (GSIS). 7 However, little is known about the mechanisms underlying the transcriptional regulation of FBP1.
Zinc finger and BTB domain-containing protein 20 (ZBTB20, also known as DPZF, HOF, and ZFP288) belongs to a subfamily of zinc finger proteins containing C2H2 Krüppel-type zinc fingers and BTB/POZ domains. 14, 15 Due to alternative translational initiation, ZBTB20 protein has 2 isoforms, both containing these 2 domains. 15 ZBTB20 plays important roles in multiple systems, as suggested by the severe phenotypes in the mice lacking ZBTB20, which mainly include growth retardation, premature death, hypoglycemia, and hippocampal defect. 16, 17 The hypoinsulinemic hypoglycemia phenotype is most likely caused by certain unknown defects beyond a feeding problem, because considerable amounts of milk are consistently present in the stomachs of Zbtb20 knockout mice, suggesting that ZBTB20 may be an important player in glucose homeostasis. 16 Given the critical role of pancreatic exocrine and endocrine cells in glucose metabolism, we analyzed expression pattern and biological functions of ZBTB20 in the pancreas. In this study, we show that ZBTB20 protein is abundantly expressed by pancreatic islet ␤ cells and plays an important role in regulating ␤ cell function through transcriptional repression of Fbp1.
Materials and Methods

Mouse Models
␤ cell-specific ZBTB20 knockout mice were generated by crossing Zbtb20 flox mice 18 with RIP-Cre transgenic mice. 19 
Metabolic Analyses
Glucose tolerance test was performed by intraperitoneal injection of D-glucose (1 g/kg body wt) into overnight-fasted mice, and insulin tolerance test was performed by intraperitoneal injection of human regular insulin (0.75 U/kg body wt; Sigma, St Louis, MO) into randomly fed mice. For in vivo insulin release assay, glucose (3 g/kg body wt) was intraperitoneally injected.
Islet Isolation and In Vitro Functional Assays
Islets were isolated from adult mice by the intraductal injection of collagenase P (Roche Diagnostics, Mannheim, Germany) and assessed for insulin secretion, glucose utilization, and ATP/adenosine diphosphate (ADP) ratios as previously described. 8 For some experiments, islets were stimulated with glucose in the presence of 30 mmol/L KCl or 250 -500 mol/L MB05032. Cellular glucose-6-phosphate (G-6-P) was detected using a G-6-P assay kit (BioVison, Mountain View, CA).
Real-Time Reverse-Transcription Polymerase Chain Reaction
Quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) was performed as previously described using total RNA. 18 PCR reaction contained SYBR Green (Invitrogen, Carlsbad, CA) and specific primers for each gene, and every plate included 36B4 gene as internal control. Primer sequences are available on request.
Reporter Assay
The mouse Fbp1 promoter (Ϫ1653 to ϩ43) was cloned into the pGL3-basic vector (Promega, Madison, WI). MIN6 cells and mouse primary hepatocytes were transiently transfected in 24-well plates with plasmids by Effectene (Qiagen, Valencia, CA). Forty-eight hours after transfection, cells were disrupted and subjected to dual luciferase assay with RL-SV40 as internal control.
RNA Interference
MIN6 cells or single cells dispersed from isolated islets were transfected with double-stranded small interfering RNA (siRNA) using siRNA transfection reagent (Dharmacon, Thermo Scientific, Lafayette, CO). Three days later, RNA interference efficiency was determined by Western blotting with anti-ZBTB20 monoclonal antibody 9A10, and insulin secretion was detected by enzyme-linked immunosorbent assay kit (Mercodia, Uppsala, Sweden). ZBTB20 siRNA sense sequence is GUCAGUAACAG-CUCCGAUAUU.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed as previously described 18 with some modifications. After crossing and sonication, cell lysates were immunoprecipitated with indicated antibodies. The eluted genomic DNA from immunoprecipitates was subjected to PCR amplification using primers for the different regions of the Fbp1 promoter (Supplementary Table 1 ).
Statistical Procedures
Unless otherwise indicated, all values are expressed as mean Ϯ SEM. Statistical analyses were performed using Student t test or analysis of variance followed by post hoc comparisons, and the null hypothesis was rejected at the .05 level.
Results
Expression of ZBTB20 in Pancreatic Endocrine Cells
To investigate the potential role of pancreatic ZBTB20 in glucose homeostasis, we first characterized its expression pattern in mouse pancreas. Immunohistochemical staining revealed that ZBTB20 protein was highly expressed by pancreatic islets and ductal cells of adult mice but absent in exocrine acini, while there was no positive staining detected in the pancreas from ZBTB20 global knockout mice ( Figure 1A ). In the islets, ZBTB20 protein was shown by double immunofluorescence staining to be abundantly expressed in insulin-producing ␤ cells, as well as in glucagon-producing ␣ cells, somatostatin-producing ␦ cells, and pancreatic polypeptide-producing pancreatic polypeptide cells ( Figure 1B ). Both isoforms of ZBTB20 were detected in mouse islets, with the short one preferentially expressed. However, in mouse ␤ cell lines MIN6 and ␤-TC, these 2 isoforms were comparably expressed at high levels ( Figure 1C ). Under pathophysiological conditions, Zbtb20 messenger RNA (mRNA) expression was markedly decreased in the islets either from diabetic db/db mice compared with their control littermates ( Figure 1D ) or from the mice fed a high-fat diet compared with those fed normal chow ( Figure 1E ). These findings implied that ZBTB20 in islet endocrine cells, especially in ␤ cells, might have a role in regulating glucose homeostasis and in the pathogenesis of diabetes.
Ablation of ZBTB20 in ␤ Cells Results in Glucose Intolerance and Impaired Insulin Secretion
To determine the role of ZBTB20 in islet ␤ cells in vivo, we used the Cre/LoxP system to generate ␤ cellspecific Zbtb20 knockout mice (hereafter referred to as ␤-ZB20KO). Mice with a floxed Zbtb20 gene 18 were crossed with the transgenic Cre mice under the control of rat insulin promoter (hereafter referred to RIP-Cre), a line that was reported to mediate loxP recombination specifically in islet ␤ cells and exhibit normal glucose tolerance. 19 -21 PCR analysis of genomic DNA showed that Zbtb20 exon 6 was efficiently disrupted in ␤-ZB20KO islets (Figure 2A and B) , and the residual signal of exon 6 reflects the unrecombined Zbtb20 flox allele, most likely from non-␤ cells in the islets. Efficient deletion of the Zbtb20 gene in ␤-ZB20KO islets was confirmed at the mRNA level by real-time RT-PCR and at the protein level by immunoblot analysis with anti-ZBTB20 antibody (Figure 2C and D) . Immunohistochemical analysis of ␤-ZB20KO islets showed that ZBTB20 protein was largely disrupted in the ␤ cells but still present in the non-␤ cells ( Figure 2E ). To evaluate the tissue specificity of RIP-Cremediated Zbtb20 deletion, we also examined ZBTB20 expression in other tissues outside the pancreas. We found that ZBTB20 protein expression was not significantly affected in hypothalamus, liver, or skeletal muscle from ␤-ZB20KO mice compared with their control counterparts ( Figure 2D and Supplementary Figure 1) , which is consistent with previous reports about this RIP-Cre line. 19, 21 Born at the expected frequencies, ␤-ZB20KO mice were fertile, grew normally, and did not differ in size or weight (Supplementary Figure 2) from their littermate controls. In addition, there was no significant difference of food intake, oxygen consumption, CO 2 production, or activity between ␤-ZB20KO and control adult mice (Supplementary Figure 3 ), indicating that ZBTB20 ablation mediated by this RIP-Cre line did not affect energy homeostasis.
To assess the effect of the ␤ cell Zbtb20 ablation on glucose homeostasis, we measured plasma glucose and insulin levels in fasted and random-fed states. At the age of 2 months, no significant difference in fasting blood glucose level was observed in either male or female ␤-ZB20KO mice compared with Zbtb20 flox/flox (hereafter referred as F/F) or heterozygous Zbtb20 flox/ϩ ;RIP-Cre (hereafter referred as F/ϩ/Cre) control littermates ( Figure 3A ). However, starting from 4 months of age, both male and female ␤-ZB20KO mice showed progressive fasting hyperglycemia ( Figure 3A) , and their fasting insulin levels were much lower than in control mice ( Figure 3B ). Then we Table 2 ). The nuclei were counterstained by 4=,6-diamidino-2-phenylindole. Scale bar ϭ 25 m. (C) Western blot analysis for ZBTB20 protein expression in mouse islets and ␤ cell lines MIN6 and ␤-TC. L, long isoform; S, short isoform. (D and E) Quantitative RT-PCR analysis for Zbtb20 mRNA expression in the islets from db/db and control mice at the age of 2 months (D) or from adult C57BL/6 mice fed a high-fat diet (HFD) or normal chow for 4 months (E). *P Ͻ .05 vs normal chow, **P Ͻ .01 vs WT.
performed the glucose tolerance test on overnight-fasted adult mice. After intraperitoneal injection of glucose at half of the regular dose, blood glucose level peaked at approximately 200 mg/dL at 15 minutes in control mice. In contrast, glucose tolerance was severely impaired in ␤-ZB20KO mice, with a peak blood glucose level of approximately 450 mg/dL at 30 -60 minutes after glucose injection ( Figure 3C ). Moreover, ␤-ZB20KO mice showed normal insulin tolerance ( Figure 3D ), indicating their glucose intolerance was most likely to result from ␤ cell dysfunction.
Then we measured plasma insulin levels after glucose stimulation and found that ␤-ZB20KO mice displayed a loss of first-phase and delayed second-phase insulin secretion ( Figure 3E ). It is noteworthy that some RIP-Cre lines themselves show impaired glucose tolerance. 22 Therefore, in these glucose tolerance and insulin secretion experiments, we included both RIP-Cre and heterozygous F/ϩ/ Cre mice as control, neither of which showed a significant difference compared with wild-type or Zbtb20 flox/flox control ( Figure 3C and E, and data not shown). These were consistent with previous reports that this RIP-Cre line has normal glucose tolerance. 19, 21 Collectively, these results suggested that the ␤ cell dysfunction in ␤-ZB20KO mice was caused by ␤ cell-specific deletion of ZBTB20.
Defects in Glucose Sensing and Insulin Secretion of ␤-ZB20KO Islets
To determine whether the ␤ cell dysfunction in ␤-ZB20KO mice was associated with morphologic abnormality, we performed histologic examination. By immunostaining of glucagon, somatostatin, and pancreatic polypeptide produced by non-␤ cells in islets, either islet architecture or ␤ cell mass did not differ between control and ␤-ZB20KO mice (Supplementary Figure 4A and B) . In addition, their pancreatic insulin content from the acidethanol extracts did not show a significant difference (Supplementary Figure 4C) .
We next evaluated glucose-induced insulin secretion from isolated islets. Upon the basal level stimulation of 3.3 mmol/L glucose, ␤-ZB20KO and control islets secreted a comparable amount of insulin ( Figure 3F ). However, when stimulated with high levels of glucose, ␤-ZB20KO islets displayed impaired insulin secretion compared with their control counterpart. Interestingly, the insulin secretion defect was glucose specific because insulin secretion was normal in response to 30 mmol/L KCl, which mediates membrane depolarization and triggers insulin secretion. This suggested that the insulin secretion pathway downstream from the ATP-sensitive K ϩ channel may be normal in ZBTB20-deficient ␤ cells, and their defect of GSIS could occur at the glucose metabolic pathway. To confirm this hypothesis, we isolated islets and measured their glucose utilization and the ratios of cellular ATP to ADP in vitro. Upon the stimulation of 3.3 mmol/L glucose, there was no significant difference of either glucose utilization or the ATP/ADP ratios between ␤-ZB20KO and control islets. However, when stimulated with high levels of glucose, ␤-ZB20KO islets showed greatly impaired glucose utilization and reduced ATP/ADP ratios compared with their control counterparts ( Figure 4A and B) . The decrease in ATP/ADP ratio is of sufficient magnitude to cause the impairment of GSIS.
To further assess glucose metabolism, we measured cellular contents of G-6-P in islets. Under basal condition, there was no significant difference of G-6-P contents between control and ␤-ZB20KO islets. To our surprise, upon stimulation with high glucose levels, ␤-ZB20KO islets had markedly increased contents of G-6-P compared with control islets ( Figure 4C ), which excluded the possibility of decreased uptake of glucose by ␤ cells and/or impaired glucose phosphorylation by glucokinase. These findings indicate that ZBTB20-deficient ␤ cells had a significant defect of glucose metabolism, most likely occurring downstream of G-6-P. We then tested nonglucose fuels entering glycolysis distal to G-6-P. ␣-Ketoisocaproate is transaminated with glutamate to leucine and ␣-ketoglutarate in ␤ cells, which, in turn, are metabolized to produce intracellular signals such as ATP for insulin secretion. 23 After stimulation with 20 mmol/L ␣-ketoisocaproate in the presence of low glucose levels, ␤-ZB20KO islets released comparable amounts of insulin relative to control islets (Supplementary Figure 5) , suggesting that glycolysis distal to G-6-P could be normal in ZBTB20-deficient ␤ cells. Taken together, we reasoned that the defects of glycolysis might occur not far from downstream G-6-P in ZBTB20-deficient ␤ cells, which at least partly contributed to the impairment of glucose sensing and insulin secretion.
Altered Gene Expression in ␤-ZB20KO Islets
To determine the molecular basis for the insulin secretion defects in response to glucose, we performed quantitative real-time RT-PCR analysis on the isolated islets. ␤-ZB20KO and control islets exhibited comparable mRNA expression levels of insulin-encoding gene Ins2, glucagon-encoding gene Gcg, somatostatin-encoding gene Sst, pancreatic polypeptide-encoding gene Ppy, peroxisome proliferator-activated receptor ␥ coactivator 1␣-encoding gene Ppargc1␣, and MODY genes Pdx1, Hnf1␣, Hnf1␤, Hnf4␣, and Gk, whereas Neuro D1 was mildly increased in ␤-ZB20KO islets (Supplementary Figure 6) . Of the glucose transporters Glut1, Glut2, and Glut3 detected, Glut1 mRNA expression was markedly reduced in (F) In vitro insulin secretion of islets after glucose stimulation (n ϭ 4). The isolated islets were stimulated with glucose at the presence or absence of KCl for 1 hour. The insulin levels in culture supernatants were normalized by total cellular insulin contents. *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001 vs control.
␤-ZB20KO islets relative to control islets, whereas Glut2
showed a trend toward increased expression (Supplementary Figure 6 ). In addition to Gk, other glycolytic genes including G6pi, Pfk, Pgm, and L-PK did not display significant changes of the mRNA expression levels in ␤-ZB20KO islets. Both Pepck and G6Pase, the key gluconeogenic genes, were detected at comparably low levels in ␤-ZB20KO and control islets, but Fbp1 mRNA was increased nearly 20-fold in ␤-ZB20KO islets, whereas Fbp2 mRNA expression was not significantly altered ( Figure  4D ). Then we confirmed FBP1 expression by Western blot and immunohistochemical analyses. Consistent with our previous report, 8 FBP1 protein was undetectable by Western blotting or immunostaining by anti-FBP1 antibodies in the normal islets from either ZBTB20 flox/flox or RIP-Cre mice. However, it was specifically detected at the high levels from the lysates of ␤-ZB20KO islets ( Figure 4E ). Immunostaining also revealed abundant expression of FBP1 protein in islet ␤ cells from ␤-ZB20KO mice ( Figure  4F ). This is consistent with the increase of cellular G-6-P at its upstream. Given the role of FBP1 in the regulation of GSIS of ␤ cells, 7, 8 we reasoned that up-regulated expression of FBP1 at least partly could lead to the impairment of glucose sensing and insulin secretion of ZBTB20-deficient ␤ cells.
Impaired Insulin Secretion and Increased Fbp1 Expression in Zbtb20 Knockdown ␤ Cells
We next investigated the role of ZBTB20 in a glucose-responsive mouse ␤ cell model. MIN6 cells were treated with ZBTB20-specific or scrambled control siRNA.
As shown in Figure 5A , treatment of ZBTB20-specific siRNA led to a significant decrease of ZBTB20 protein in MIN6 cells, whereas scrambled siRNA had no effect on ZBTB20 protein levels. Seventy-two hours after siRNA transfection, MIN6 cells were stimulated with glucose to test their insulin secretion. Compared with scrambled siRNA-transfected control, ZBTB20 knockdown MIN6 
BASIC AND TRANSLATIONAL
PANCREAS
cells had comparable cellular insulin contents and basal insulin secretion at 1.1 mmol/L glucose but secreted much lower levels of insulin at 11 mmol/L glucose ( Figure  5B ). Moreover, increased expression of Fbp1 mRNA was detected by RT-PCR in Zbtb20 knockdown MIN6 cells or islets ( Figure 5C and D) . These results were consistent with that of ␤-ZB20KO islets, supporting the conclusion that ZBTB20 regulates Fbp1 expression and insulin secretion in ␤ cells.
Restored Insulin Secretion by Inhibition of FBPase Activity
To determine whether FBP1 is a major mediator in the impaired GSIS of ZBTB20-deficient ␤ cells, we took a pharmacologic approach to block FBP1 activity in the islets during glucose stimulation. Consistent with our previous observation, 8 treatment with 250 mol/L MB05032, a specific inhibitor of FBPase, 24 markedly enhanced GSIS from control islets at 3.3 or 25 mmol/L glucose. ␤-ZB20KO islets treated with 250 mol/L MB05032 showed an increasing tendency of insulin secretion at 3.3 mmol/L glucose, but it did not reach statistical significance. Upon stimulation with 25 mmol/L glucose, 250 mol/L MB05032-treated ␤-ZB20KO islets secreted significantly higher levels of insulin compared with the vehicle mock control, however, which was much lower than that of control islets treated with 250 mol/L MB05032 ( Figure 6A and B) . Considering the robust expression of FBP1 protein in ␤-ZB20KO islets, we reasoned that a higher dose of MB05032 might be required to block its activity in ␤ cells. Therefore, we treated ␤-ZB20KO and control islets with 500 mol/L MB05032. The insulin secretion levels of control islets at 3.3 and 25 mmol/L glucose in the presence of 500 mol/L MB05032 were further mildly increased compared with 250 mol/L MB05032. Importantly, ␤-ZB20KO and control islets treated with 500 mol/L MB05032 secreted comparable levels of insulin at basal and stimulatory doses of glucose, suggesting that blockade of the increased FBP1 activity in ZBTB20-deficient ␤ cells could restore their glucose-stimulated insulin secretion. Consistently, treatment of 500 mol/L MB05032 also led to significant restoration of glucose utilization and ATP/ADP ratios in ␤-ZB20KO islets at 25 mmol/L glucose ( Figure 6C and D) . These findings suggested that up-regulated FBP1 protein in ZBTB20-deficient ␤ cells might mainly contribute to the impairment of glucose sensing and insulin secretion.
ZBTB20 Regulates Fbp1 Gene Transcription in ␤ Cells
To biochemically determine the direct evidence about the regulation of Fbp1 gene transcription by ZBTB20, we first performed ChIP assay to examine the physiologic occupancy of ZBTB20 on the Fbp1 promoter. In MIN6 cells, ChIP assays were performed with antibodies against ZBTB20, acetylated histone 3 (AcH3, positive control), or control immunoglobulin G as negative control of chromatin recovery, and the recovered chromatin DNA was subjected to PCR analysis using 3 different primer sets for Fbp1 gene and its upstream loci. As shown in Figure 7 , ZBTB20 was recruited on the Fbp1 promoter spanning about 1 kilobase upstream the transcriptional start site, but not in the unrelated region located 6 kilobases distal to the Fbp1 gene in MIN6 cells. We further performed ChIP assay on pooled mouse islets and found consistently that ZBTB20 occupied on the Fbp1 promoter in pancreatic islets.
We next cloned the regulatory region spanning Ϫ1653 to ϩ43 of the Fbp1 gene and constructed luciferase reporter to test whether ZBTB20 might be capable of repressing Fbp1 promoter activity. Transient overexpression of ZBTB20 in MIN6 cells failed to affect the activity of Fbp1 promoter-driven luciferase reporter ( Figure 7D) , probably due to their abundant expression of endogenous ZBTB20 protein. On the other hand, ZBTB20 knockdown in MIN6 cells by siRNA treatment resulted in a significant increase of the Fbp1 promoter-driven reporter activity ( Figure 7E ), indicating that ZBTB20 could repress the transcriptional activity of the Fbp1 promoter. Combined with the data of increased expression of Fbp1 both in ␤-ZB20KO islets and in ZBTB20 knockdown MIN6 cells, these data suggested that ZBTB20 act as a transcriptional repressor of the Fbp1 gene in ␤ cells.
ZBTB20 Regulates FBP1 Gene Transcription in Hepatocytes
Considering that both Zbtb20 and Fbp1 are also expressed in hepatocytes, we further assessed whether ZBTB20 regulated Fbp1 gene transcription in the liver. To this end, we first examined whether ZBTB20 disruption in hepatocytes led to dysregulated Fbp1 expression and found that Fbp1 mRNA levels were increased 40% in the livers from hepatocyte-specific Zbtb20 knockout mice compared with their littermate control (Supplementary Figure 7A) . Moreover, transient overexpression of ZBTB20 in primary ZBTB20-null hepatocytes resulted in dramatic inhibition of Fbp1 promoter-driven transcription activity (Supplementary Figure 7B) . ChIP assay revealed that ZBTB20 was robustly recruited to the Fbp1 promoter in the liver (Supplementary Figure 7C and D) . Taken together, these data suggested that ZBTB20 could repress Fbp1 gene transcription both in ␤ cells and in hepatocytes.
Discussion
Regulation of GSIS by ZBTB20
In the present study, we examined the role of ZBTB20 in ␤ cell biology and function. Our findings provide compelling evidence that ␤ cell ZBTB20 regulates glucose sensing and insulin secretion via transcriptional repression of FBP1. First, Zbtb20 gene is abundantly expressed in islet ␤ cells. Second, ␤ cell-specific ablation of Zbtb20 results in decreased glucose utilization and ATP production, as well as impaired insulin secretion. Similar results can be obtained in ␤ cell lines by RNA interference. The ␤ cell defect is relatively glucose specific, because the insulin secretion was normal in response to KCl stimulation. Third, Fbp1 gene expression is up-regulated both in ZBTB20-deficient ␤ cells and in Zbtb20 siRNA-treated ␤ cells or islets. FBP1 acts as a regulator of GSIS in ␤ cells, and its up-regulation results in the impairment of GSIS. 7, 8 Blockage of FBP1 activity with its specific inhibitor MB05032 completely restored the impaired glucose utilization and insulin secretion of ZBTB20-deficient islets in vitro. This provides additional evidence to support inhibition of FBP1 as a therapeutic target for the treatment of T2DM. Last, ZBTB20 directly regulates Fbp1 transcription in ␤ cells. ZBTB20 binds to Fbp1 promoter by ChIP assay and functions as a transcriptional repressor of the Fbp1 gene. The transcription regulatory mechanism of ZBTB20 is under further investigation. Taken together, our results for the first time establish the role of ZBTB20 in ␤ cell function and identify Fbp1 as one of its target genes in ␤ cells.
FBP1 Regulation in ␤ Cell Dysfunction
As a gluconeogenic enzyme, FBP1 is critical for liver endogenous glucose production. FBP1 was recently recognized as an important regulator of glucose metabolism and insulin secretion of ␤ cells. 7, 8 By coupling with PFK and finely tuning the conversion between fructose- 1,6-bisphosphate and fructose-6-phosphate, FBPase controls the glycolytic/gluconeogenic flux, decreasing substrate availability for glycolysis. The physiologic role of FBP1 in ␤ cells is neglected due to its low expression. Our previous work found that FBP1 mRNA levels in mouse islets were 20-fold higher than that in muscle, and treatment of mouse islets with FBP1 inhibitor could robustly augment GSIS both in vitro and in vivo, which argues its physiologic functions in ␤ cells. 8 Nevertheless, the regulatory mechanisms of Fbp1 expression in ␤ cells remain elusive. Our results suggest that low expression of Fbp1 in normal ␤ cells is mainly due to the negative regulation by ZBTB20. Thus, we postulate that ZBTB20 functions as a physiologic facilitator of GSIS in ␤ cells through transcriptional repression of Fbp1. This extends our knowledge about the regulatory networks of glucose-sensing machinery and insulin secretion in ␤ cells and highlights the critical role of regulated Fbp1 in ␤ cell function.
In diabetic human and rodent islets, Fbp1 expression is significantly increased, which can be a contributing factor in the impairment of GSIS. 7 Given the critical role of ZBTB20 in the transcriptional regulation of Fbp1, we reason that the dysregulated Fbp1 expression in ␤ cells may result from decreased expression and/or compromised repressive activity of ZBTB20, which is partly confirmed by our observation of decreased Zbtb20 expression in diabetic islets. Subjects with T2DM characteristically have pronounced impairment of first-phase insulin secretion. 25, 26 This defect is islet intrinsic and relatively glucose specific in the earlier stages of the disease. 27, 28 Some factors (eg, hypoxia-inducible factor 1␣ and ARNT/hypoxiainducible factor 1␤) have been shown to contribute to altered function of diabetic ␤ cells. 29, 30 Our results suggest that ZBTB20 may be another important player in ␤ cell dysfunction during the pathogenesis of T2DM.
T2DM is a genetically heterogeneous disease, with the most common forms resulting from the complex interplay of many different pathways under the control of genetic and environmental factors. 31 In humans, it is unlikely that a genetic alteration of ZBTB20 itself causes the disease, because the mice lacking ZBTB20 have severe hypoglycemia and high premature mortality. 16 Besides ␤ cells, Zbtb20 is also widely expressed in islet non-␤ endocrine cells, brain, skeletal muscle, heart, kidney, and liver, 18 which raises the possibility that its essential role in glucose homeostasis may be mediated by different tissues and mechanisms. In the whole body Zbtb20 knockout mice, altered ␤ cell function is probably masked by the phenotype of severe hypoglycemia, with hypoinsulinemia being a probable compensatory response. Therefore, we speculate that the pathogenic significance of ZBTB20 in T2DM is probably associated with its decreased expression or functional abnormality in ␤ cells, which may result from the combination of acquired and genetic alterations.
In summary, these studies show that ␤ cell ZBTB20 regulates glucose-stimulated insulin secretion through transcriptional repression of Fbp1, which helps to unravel the biochemical basis of ␤ cell dysfunction in T2DM and to validate Fbp1 as a potential therapeutic target for the treatment of T2DM.
Western Blot Analysis
Total cellular lysate was extracted with a buffer containing 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L Na 3 VO 4 , 1 mmol/L NaF, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride, 1 g/mL leupeptin, 1 g/mL aprotinin, and 1 g/mL pepstatin. Protein lysates (50 g/lane) were resolved by sodium dodecyl sulfate/polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (PolyScreen; PerkinElmer), and incubated with the appropriate primary antibody by standard protocols. After probing with horseradish peroxidase-conjugated secondary antibodies, immunoreactive proteins were visualized with ECL Western blotting detection reagents (Pierce Biotechnology, Rockford, IL).
Mouse Primary Hepatocyte Isolations
Mouse primary hepatocytes were isolated by perfusion followed by collagenase digestion using commercial reagents (Invitrogen, Carlsbad, CA). Cells were resuspended in M199 media supplemented with 10% fetal bovine serum, plated in 24 well-plates at a density of 1.2 ϫ 10 6 cells per well, and allowed to attach for 6 -7 hours.
Reporter Assay
Mouse Zbtb20 expression vector was previously described. 1 The mouse Fbp1 promoter (Ϫ1653 to ϩ43) was cloned by PCR, confirmed by DNA sequencing, and inserted into the pGL3-basic vector (Promega). MIN6 cells and mouse primary hepatocytes were transiently transfected in 24-well plates with plasmids by Effectene (Qiagen). Forty-eight hours after transfection, cells were disrupted with passive lysis buffer (Promega) and subjected to a luminescent assay in a luminometer (MiniLumat LB9506; Berthold GmbH, Bad Wildbad, Germany). SV40-Renilla luciferase plasmid was used as an internal control to normalize the luciferase activity. The fold repression of transcription was calculated relative to transcription of the reporters in the presence of the relevant empty expression vector and normalized to the internal control. Expression of all of the transfected proteins was confirmed by immunoblotting with the appropriate antibodies.
ChIP Assay
ChIP assays were performed as described previously 8 with some modifications. Islets were pooled from 12 normal adult mice. Briefly, hepatocytes, MIN6 cells, or islets were resuspended in 10 mL phosphate-buffered saline containing 1.42% formaldehyde and incubated at room temperature for 15 minutes to cross-link protein to DNA. Cross-linked cells were washed twice with phosphate-buffered saline and once with IP buffer (0.5% Nonidet P-40, 1% Triton X-100, 50 mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 5 mmol/L EDTA, 1 g/mL aprotinin, 2 g/mL leupeptin). Lysates were sonicated and immunoprecipitated with acetylated histone H3 (Upstate, Billerica, MA), rabbit polyclonal anti-ZBTB20 antibody, or control rabbit immunoglobulin G (Upstate). Immune complexes were precipitated by using protein A-agarose (Roche) and washed 5 times with IP buffer. Immunoprecipitated genomic DNA was eluted by boiling for 10 minutes in 10% Chelex 100 beads (Bio-Rad, Hercules, CA) and then used for real-time PCR with primers designed to amplify proximal promoter regions (Supplementary Table 1 ).
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